Maharashtra FDA Seizes ₹11.41 Crore Stock in 3 Months

Maharashtra's Food and Drug Administration (FDA) has carried out 104 search-and-seizure operations in just three months, seizing illegal medicines and cosmetics worth ₹11.41 crore. This significant increase in enforcement action has been seen after FDA Commissioner Tukaram Mundhe took charge.

The latest action has exposed potentially hazardous products, including Pakistan-made skin-whitening creams containing excessive mercury and, in some cases, lead. Several imported face creams were found without mandatory documents and import papers, while the FDA also flagged spurious and substandard medicines.

The 104 operations conducted in just three months account for nearly one-fourth of the total 419 operations recorded over the previous five financial years. While the periods are not directly comparable, the figures indicate a sharp escalation in enforcement under Mundhe.

The action targeted several skin-whitening products, including Goree Beauty Cream, Golden Star Beauty Cream and Face Fresh Gold Beauty Cream and Serum, which were flagged following testing by the FDA. The presence of excessive mercury and lead in such products can pose health risks to consumers.

Among medicines, the FDA declared Diabeties-ALL spurious, while Edengrel 75 mg (clopidogrel) failed the dissolution test. Clopidogrel is used to prevent blood clots and reduce the risk of heart attacks and strokes.

The violations detected during inspections ranged from the manufacture and sale of unauthorised or substandard medicines to deficiencies in quality-control procedures and production records. In some establishments, medicines were being sold without the supervision of registered pharmacists and without proper bills.

The FDA also found scheduled medicines being sold without prescriptions, improper handling of expired medicines and poor storage of temperature-sensitive medicines such as insulin and vaccines. Improper storage can compromise the effectiveness of such products.

The three-month action resulted in 20 FIRs and 21 arrests, according to the FDA data. This crackdown is a significant step towards ensuring public health and safety in Maharashtra.

The FDA's increased enforcement action is a result of Commissioner Tukaram Mundhe's efforts to strengthen the regulatory framework and protect consumers from hazardous products. The seizures and arrests made during this period demonstrate the FDA's commitment to upholding the law and ensuring that only safe and effective products are available in the market.

In the context of Maharashtra's healthcare landscape, this crackdown is a crucial step towards preventing the sale of spurious and substandard medicines. The FDA's actions will help to safeguard public health and prevent unnecessary harm to consumers.

The significance of this crackdown cannot be overstated, as it highlights the importance of regulatory enforcement in protecting public health. The FDA's efforts will have a positive impact on the healthcare sector in Maharashtra, and it is essential to continue this momentum to ensure that consumers have access to safe and effective products.

In conclusion, the Maharashtra FDA's intensified crackdown under Commissioner Tukaram Mundhe is a significant development in the state's healthcare landscape. The seizures and arrests made during this period demonstrate the FDA's commitment to upholding the law and ensuring public health and safety. This crackdown will have a lasting impact on the healthcare sector in Maharashtra and will help to prevent the sale of hazardous products.